Amgen Inc. logo

Amgen Inc. (AMGN)

Market Open
5 Dec, 20:41
NASDAQ (NGS) NASDAQ (NGS)
$
330. 48
-9.68
-2.85%
$
185.54B Market Cap
19.61 P/E Ratio
9% Div Yield
1,588,297 Volume
18.58 Eps
$ 340.16
Previous Close
Day Range
329.56 340.88
Year Range
253.3 346.38
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 59 days
Trade Tracker: Kevin Simpson buys Howmet, buys more Amgen

Trade Tracker: Kevin Simpson buys Howmet, buys more Amgen

Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.

Youtube | 8 months ago
2 Surefire Dividend Stocks That Could Pay You for Life

2 Surefire Dividend Stocks That Could Pay You for Life

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust underlying operations.

Fool | 8 months ago
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 8 months ago
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom

Biopharma firms with foreign exposure face disruption as Trump's tariffs loom

The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.

Proactiveinvestors | 8 months ago
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity

Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity

Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.

Youtube | 8 months ago
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.

Fool | 8 months ago
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note

Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.

Zacks | 8 months ago
Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 8 months ago
Why the Market Dipped But Amgen (AMGN) Gained Today

Why the Market Dipped But Amgen (AMGN) Gained Today

Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.

Zacks | 8 months ago
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?

Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Zacks | 8 months ago
Prediction: These 2 Stocks Will Outperform the Market Through 2030

Prediction: These 2 Stocks Will Outperform the Market Through 2030

Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns.

Fool | 8 months ago
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.

Zacks | 8 months ago
Loading...
Load More